Niagen Bioscience, Inc. — Director's Dealing 2022

Jun 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2022-06-16

Reporting Person: Rubin Steven D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-16	Stock Option (right to buy)	$1.64	A	20000	Acquired	2032-06-15	Common Stock (20000.0)	Direct

Footnotes

F1: Option vests 100% on June 16, 2023.